Clinical Trials Logo

Seizures clinical trials

View clinical trials related to Seizures.

Filter by:

NCT ID: NCT04325685 Completed - Clinical trials for Acute Respiratory Distress Syndrome

The Effect of Supraglottic and Oropharyngeal Decontamination on the Incidence of Ventilator-associated Pneumonia

SGDC-VAP
Start date: January 1, 2020
Phase: N/A
Study type: Interventional

Oropharynx is the main source of pathogen microorganisms for the ventilator - associated pneumoniae. As known bacteriophages can eliminate different pathogen microorganisms or reduce a degree of a pathogen's colonization. The research team is considering that oropharyngeal decontamination with bacteriophages can prevent the developing of the ventilator - associated pneumoniae. There will be three groups in this investigation: placebo, antiseptic drug (Octenisept) and bacteriophage (Sexthaphag).

NCT ID: NCT04323150 Completed - Seizures Clinical Trials

The Effect of Closed Suction System on the Incidence of Ventilator-associated Pneumonia.

CSS-VAP
Start date: February 1, 2018
Phase: N/A
Study type: Interventional

The investigators are suggesting that closed suction systems may reduce the risk of the ventilator - associated pneumoniae (VAP) and the contamination of the closest unanimated surfaces. In 2011 David et al. have shown that closed suction systems might reduce the incidence of the late VAP. Research team is thinking that preventive bundle with closed suction systems can prevent to onset of the VAP. All enrolled patients is randomizing into two groups: control group - conventional suctioning and research group - suctioning with closed suction system.

NCT ID: NCT04320940 Terminated - Clinical trials for Epilepsy, Benign Neonatal

Efficacy and Safety of Intravenous Phenobarbital in Neonatal Seizures

Start date: March 12, 2021
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, parallel-group, Phase 3 study to evaluate the efficacy of the administration of phenobarbital sodium injection in neonates who have suffered from electrographic or electroclinical seizure. As neonatal seizures can have long-term adverse effects, including death, placebo-controlled studies are not appropriate for this population. This study is designed to show intravenous phenobarbital is effective at preventing subsequent seizures by demonstrating greater efficacy at a higher dose compared to a lower dose.

NCT ID: NCT04311151 Completed - Epilepsy Clinical Trials

Impact of Self-visualization of Epileptic Seizures on Patients' Perception of the Disease and Risk Behavior

VICE
Start date: January 12, 2017
Phase: N/A
Study type: Interventional

In Spain, an estimated 690,000 persons have epilepsy, of whom 270,000 have active epilepsy (defined as those who have had a seizure in the last 5 years). It is estimated that 30% of patients diagnosed with epilepsy are drug-resistant. Patients with loss of consciousness or impaired awareness during seizures are at higher risk of injury due to accidents. To prevent such injuries, it is important that patients are sufficiently knowledgeable about their disease to allow them to avoid risk behavior. In this project, we want to know if visualization of self seizures has an impact on the perception of the severity of the disease, as well as on the risky behavior habits.

NCT ID: NCT04291716 Not yet recruiting - Epilepsy Clinical Trials

Study to Validate Novel Seizure-Detection Algorithm

Start date: March 2020
Phase: N/A
Study type: Interventional

The specificity and sensitivity of a novel seizure-detection mobile software application with a generalized tonic/clonic seizure detection algorithm (Motor Seizure Detection Algorithm [mSDA]) installed on a wearable device to be worn by the subject. The software will be tested using subjects from a patient population in an epilepsy monitoring unit (EMU) undergoing video and electroencephalograph (VEEG) observation. The number of generalized major motor seizures detected by the mSDA will be compared with those detected by VEEG.

NCT ID: NCT04284072 Completed - Epilepsy Clinical Trials

Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology

SeizeIT2
Start date: June 22, 2020
Phase: N/A
Study type: Interventional

Clinically validate a biopotential and motion recording wearable device (Byteflies Sensor Dot) for detection of epileptic seizures in the epilepsy monitoring unit (EMU) and at home.

NCT ID: NCT04266990 Terminated - Epilepsy Clinical Trials

Olfactive Discriminative Ability of Dogs When Confronted With Seizure and Non-seizure Samples // Identification of Potential Biomarkers for Epilepsy in Human Sweat.

Start date: January 20, 2020
Phase: N/A
Study type: Interventional

Dogs belonging to MDD will be trained and asked to discriminate between odour sweat samples from epilepsy patients associated with a seizure ("seizure sample") and samples collected when no seizure was close in time ("non-seizure sample"). The same type positive and negative sweat samples will be analysed by Florida International University using solid phase micro extraction (SPME) GC-MS to try to identify volatile organic components (VOC) specific to the samples associated with seizures.

NCT ID: NCT04259125 Active, not recruiting - Epilepsy Clinical Trials

Evaluating the Role of Inflammation in Neonatal Epileptogenesis

NSR-RISE
Start date: December 15, 2018
Phase:
Study type: Observational

The purpose of this study evaluate the relationship between inflammation and epilepsy in neonates with seizures after birth.

NCT ID: NCT04257604 Completed - Partial Seizures Clinical Trials

A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures

Start date: January 3, 2016
Phase:
Study type: Observational

The primary objective of the present study will be to assess the effectiveness of add-on perampanel in participants with focal seizures in a real-life clinical setting.

NCT ID: NCT04252846 Completed - Clinical trials for Partial Onset Seizures

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Start date: July 20, 2020
Phase:
Study type: Observational

The primary purpose of this study is to assess the retention rate of perampanel as a reliable proxy for overall effectiveness and tolerability in participants aged at least 12 years who are prescribed perampanel (for partial onset seizures [POS] with or without secondary generalization [SG] or for primary generalized tonic-clonic seizures [PGTCS] associated with idiopathic generalized epilepsy [IGE] as first adjunctive to antiepileptic drug (AED) monotherapy as part of their routine clinical care.